Banco Santander S.A. Invests $1.16 Million in Medpace Holdings, Inc. (NASDAQ:MEDP)

Key Points

• Banco Santander S.A. has acquired 3,796 shares of Medpace Holdings, Inc., valued at approximately $1,157,000, as noted in its recent SEC filing.
• Medpace's stock performances have led several analysts to revise their price targets significantly, with Mizuho raising it from $328.00 to $510.00 and Truist Financial moving it from $298.00 to $436.00.
• Insider selling has been notable, with CEO August J. Troendle selling 48,487 shares valued at over $21.9 million, indicating a 4.80% decrease in ownership.

Banco Santander S.A. purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 3,796 shares of the company's stock, valued at approximately $1,157,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MEDP. Sone Capital Management LLC bought a new stake in Medpace during the fourth quarter valued at approximately $1,318,000. GAMMA Investing LLC grew its stake in shares of Medpace by 37.1% in the 1st quarter. GAMMA Investing LLC now owns 307 shares of the company's stock worth $94,000 after buying an additional 83 shares during the last quarter. Fundsmith LLP bought a new stake in Medpace in the 4th quarter worth about $42,372,000. Park Avenue Securities LLC boosted its position in Medpace by 1.8% in the first quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock worth $838,000 after purchasing an additional 48 shares during the last quarter. Finally, UMB Bank n.a. grew its stake in shares of Medpace by 70.7% during the 1st quarter. UMB Bank n.a. now owns 490 shares of the company's stock valued at $149,000 after acquiring an additional 203 shares during the period. Institutional investors own 77.98% of the company's stock.

Medpace Price Performance

Shares of NASDAQ:MEDP traded down $1.34 during trading on Thursday, reaching $429.03. The company had a trading volume of 232,928 shares, compared to its average volume of 460,318. The firm has a market capitalization of $12.05 billion, a price-to-earnings ratio of 31.90, a price-to-earnings-growth ratio of 2.75 and a beta of 1.42. The stock's fifty day moving average price is $339.02 and its 200 day moving average price is $325.40. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $501.30.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping the consensus estimate of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The firm had revenue of $603.31 million during the quarter, compared to analyst estimates of $537.70 million. During the same quarter in the prior year, the business posted $2.75 earnings per share. Medpace's revenue for the quarter was up 14.2% compared to the same quarter last year. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Transactions at Medpace

In other Medpace news, VP Susan E. Burwig sold 7,500 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $450.14, for a total transaction of $3,376,050.00. Following the completion of the transaction, the vice president directly owned 57,500 shares of the company's stock, valued at $25,883,050. The trade was a 11.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Kevin M. Brady sold 12,000 shares of Medpace stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the completion of the transaction, the chief financial officer owned 6,000 shares in the company, valued at approximately $2,725,380. This trade represents a 66.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 112,788 shares of company stock valued at $51,018,354 over the last quarter. Insiders own 20.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Robert W. Baird lifted their price target on shares of Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft increased their target price on Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. TD Cowen reissued a "sell" rating and issued a $366.00 price target (up previously from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Mizuho increased their price target on Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Finally, Barclays upped their price objective on shares of Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $406.60.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.